新诊断小肠克罗恩病儿童及青年患者肠道MRI体素内不相干运动的 prospective 特征分析
这项前瞻性病例对照研究纳入20例新诊断回肠克罗恩病儿童患者和15例健康儿童,采用九b值DWI-IVIM序列测量回肠末端IVIM参数。克罗恩病患者诊断时D、D*、f均低于健康对照,抗TNF-α治疗后f和D*随时间升高,而D无显著变化。
要点
- 新诊断回肠克罗恩病患儿回肠末端IVIM参数D、D*、f均低于健康儿童。
- 抗TNF-α治疗后IVIM f从基线22%升至6个月29%,D*从10.9升至13.3×10⁻³ mm²/s。
- IVIM D在治疗后无显著变化(P=0.10)。
核心结论
- 回肠克罗恩病患者MRI DWI-IVIM参数随生物制剂治疗变化,并有助于区分患者与健康参与者。
研究设计与样本
- 前瞻性病例对照研究,20例连续新诊断回肠克罗恩病儿童患者(平均年龄14岁±2,8例女性)和15例健康儿童参与者(平均年龄18岁±4,8例女性),2018年12月至2021年10月行小肠研究性MRI,采用九b值DWI-IVIM序列提取D、D*、f参数,克罗恩病患者在抗TNF-α治疗基线、6周和6个月复查,对照仅检查一次,使用非配对t检验和混合效应模型分析。
诊断标准与关键数值
- 诊断时克罗恩病患者平均IVIM D低于健康参与者(P<0.001)。
- 诊断时克罗恩病患者平均IVIM D*低于健康参与者(P=0.004)。
- 诊断时克罗恩病患者平均IVIM f低于健康参与者(P=0.001)。
- 抗TNF-α治疗后平均IVIM f随时间升高:基线22%±6%,6周25%±7%,6个月29%±10%(P=0.016)。
- 抗TNF-α治疗后平均IVIM D*随时间升高:基线10.9±3.0×10⁻³ mm²/s,6周11.8±2.8×10⁻³ mm²/s,6个月13.3±3.3×10⁻³ mm²/s(P=0.047)。
临床应用与阅片要点
- 作者认为MRI DWI-IVIM参数可用于区分新诊断回肠克罗恩病患者与健康参与者。
- 作者认为IVIM f和D*可反映抗TNF-α治疗后的变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: MRI diffusion-weighted imaging (DWI) is commonly used in MR enterography protocols for assessment of intestinal inflammation in patients with Crohn's disease. The intravoxel incoherent motion (IVIM) approach to DWI has been proposed as a more objective approach, providing quantitative parameters that reflect water diffusivity (D), blood flow (D*), and perfusion fraction (f).
PURPOSE: We aimed to determine if DWI-IVIM metrics from the terminal ileum in patients with newly diagnosed Crohn's disease differ from healthy participants and change in response to biologic medical therapy.
METHODS: In this prospective case-control study, 20 consecutive pediatric patients (mean age = 14 years ± 2 [SD]; eight females) with newly diagnosed ileal Crohn's disease and 15 pediatric healthy participants (mean age = 18 years ± 4 [SD]; eight females) underwent research MRI examinations of the small bowel between 12/2018 and 10/2021. Participants with Crohn's disease underwent MR studies at baseline, 6 weeks, and 6 months following initiation of anti-TNF-alpha therapy, whereas control participants underwent one research MRI examination. The MRI protocol included a DWI-IVIM sequence with nine b-values and the IVIM parameters (D, D*, and f) were extracted. Unpaired t-tests and mixed-effects models were used for analyses.
RESULTS: Mean IVIM D (P < 0.001), D* (P = 0.004), and f (P = 0.001) metrics were lower for Crohn's patients at the time of diagnosis compared to healthy participants. Mean IVIM f value increased over time in response to medical therapy (mean f at baseline, 22% ± 6%; 6 weeks, 25% ± 7%; 6 months, 29% ± 10%; P = 0.016). Mean IVIM D* value increased over time in response to treatment (mean D* at baseline, 10.9 ± 3.0 × 10-3 mm2/s; 6 weeks, 11.8 ± 2.8 × 10-3 mm2/s; 6 months, 13.3 ± 3.3 × 10-3 mm2/s; P = 0.047), while there was no significant change in mean IVIM D value (P = 0.10).
CONCLUSION: MRI DWI-IVIM metrics in patients with ileal Crohn's disease change over time in response to biological therapy and help discriminate these patients from healthy participants.
引用
- Alves VPV, Mahalingam N, Tkach JA, et al. Prospective characterization of intestinal MRI intravoxel incoherent motion in pediatric and young adult patients with newly diagnosed small bowel Crohn's disease. Abdom Radiol (NY). 2024. PMID: 38724774. doi:10.1007/s00261-024-04318-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。